Fibrates therapy: Rational use fenofibrate 2016. Executive summary

Angel Brea, Jesús Millán, Juan F. Ascaso, Mariano Blasco, Angel Díaz, Pedro González-Santos, Antonio Hernández-Mijares, Teresa Mantilla, Juan C. Pedro-Botet, Xavier Pintó

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)


© 2016 Sociedad Española de Arteriosclerosis To control lipid factors risk, beyond proper management of LDL cholesterol according to individual risk, detection and treatment of atherogenic dyslipidemia and abnormal levels of triglycerides or HDL cholesterol it should be considered for address a global cardiovascular protection, both in primary and secondary prevention. In this sense, these recommendations collect data on efficacy and safety about the combination statin with fibrates, often necessary for total control of dyslipidemia, particularly in patients with metabolic disorders such as diabetes mellitus, metabolic syndrome or visceral obesity. Reference to control and monitoring of treatment is also done, as well as benefits of fenofibrate not linked directly to their lipid-lowering effect.
Original languageEnglish
Pages (from-to)295-301
JournalClinica e Investigacion en Arteriosclerosis
Issue number6
Publication statusPublished - 1 Nov 2016


  • Atherogenic dyslipidemia
  • Cardiovascular risk
  • Fenofibrate
  • Fibrates
  • Triglycerides


Dive into the research topics of 'Fibrates therapy: Rational use fenofibrate 2016. Executive summary'. Together they form a unique fingerprint.

Cite this